Cancer Prevention Research CR Magazine 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Prevention Research 1, 233, September 1, 2008. Published Online First March 19, 2008;
doi: 10.1158/1940-6207.CAPR-07-0008
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Figures 1-4
Right arrow Perspective on This Article
Right arrow All Versions of this Article:
1940-6207.CAPR-07-0008v1
1/4/233    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoo, C. B.
Right arrow Articles by Jones, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoo, C. B.
Right arrow Articles by Jones, P. A.
Related Collections
Right arrowCommentary

Research Articles

Long-term Epigenetic Therapy with Oral Zebularine Has Minimal Side Effects and Prevents Intestinal Tumors in Mice

Christine B. Yoo1, Jody C. Chuang1, Hyang-Min Byun4,5, Gerda Egger6, Allen S. Yang4,6, Louis Dubeau5,6, Tiffany Long3,6, Peter W. Laird1,3,6, Victor E. Marquez7 and Peter A. Jones1,2,6

Authors' Affiliations: Departments of 1 Biochemistry and Molecular Biology, 2 Urology, 3 Surgery, 4 Hematology, and 5 Pathology, and 6 USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California; and 7 Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute-Frederick, Frederick, Maryland

Requests for reprints: Peter A. Jones, USC/Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Avenue, Room 8302L, Mail Stop 83, Los Angeles, CA 90033-9181. Phone: 323-865-0816; Fax: 323-865-0102; E-mail: jones_p{at}ccnt.hsc.usc.edu.


Recent successes in the application of epigenetic drugs for the treatment of myelodysplastic syndrome have raised questions on the safety of long-term administration of DNA methylation inhibitors. We treated preweaned cancer prone ApcMin/+ (Min) mice continuously with the DNA methylation inhibitor zebularine in their drinking water to determine the effects of the drug on normal mouse development as well as cancer prevention. Zebularine caused a tissue-specific reduction in DNA methylation at B1 short interspersed nucleotide elements in the small and large intestines of female Min mice but not in other organs examined after chronic oral treatment. No significant difference in the average weights of mice was observed during the treatment. In addition, analysis of global gene expression of colonic epithelial cells from the females indicated that only 3% to 6% of the genes were affected in their expression. We did not detect toxicity and abnormalities from the histopathologic analysis of liver and intestinal tissues. Lastly, we tested whether prevention of tumorigenesis can be achieved with chronic oral administration of zebularine in Min mice. The average number of polyps in Min females decreased from 58 to 1, whereas the average polyp number remained unaffected in Min males possibly due to differential activity of aldehyde oxidase. Taken together, our results show for the first time that long-term oral administration of zebularine causes a gender-specific abrogation of intestinal tumors while causing a tissue-specific DNA demethylation. Importantly, prolonged treatment of mice with epigenetic drugs resulted in only minor developmental and histologic changes.

Key Words: zebularine • epigenetic therapy • chemoprevention • DNA methylation


Commentary

Cancer Prevention: Epigenetics Steps Up to the Plate
Jean-Pierre Issa
Cancer Prevention Research 2008 1: 219-222. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cancer Prevention ResearchHome page
S. R. Morey Kinney, W. Zhang, M. Pascual, J. M. Greally, B. M. Gillard, E. Karasik, B. A. Foster, and A. R. Karpf
Lack of Evidence for Green Tea Polyphenols as DNA Methylation Inhibitors in Murine Prostate
Cancer Prevention Research, December 1, 2009; 2(12): 1065 - 1075.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
X.-H. Tang, M. Albert, T. Scognamiglio, and L. J. Gudas
A DNA Methyltransferase Inhibitor and All-trans Retinoic Acid Reduce Oral Cavity Carcinogenesis Induced by the Carcinogen 4-Nitroquinoline 1-Oxide
Cancer Prevention Research, December 1, 2009; 2(12): 1100 - 1110.
[Abstract] [Full Text] [PDF]


Home page
Cancer Prevention ResearchHome page
K. Konishi, L. Shen, J. Jelinek, Y. Watanabe, S. Ahmed, K. Kaneko, M. Kogo, T. Takano, M. Imawari, S. R. Hamilton, et al.
Concordant DNA Methylation in Synchronous Colorectal Carcinomas
Cancer Prevention Research, September 1, 2009; 2(9): 814 - 822.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.